Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Warfarin Approved for Pediatric Use: Eisai
March 7, 2011
- Korosho Calls on Generic Firms to Apply for New Indications Based on Data from Public Domain
March 7, 2011
- HbA1c to Be Reported in Int'l Units from April 2012 at the Earliest
March 7, 2011
- Higher Dose of Finibax Recommended for Approval
March 7, 2011
- 5 Brands of New Class 1 OTC Drugs Recommended for Approval
March 7, 2011
- Merck Serono Aims to Increase Market Share for Saizen
March 7, 2011
- Chuikyo to Weigh Premium-Derived Profits, Cost of Development of Unapproved Drugs
March 7, 2011
- Fuji Pharma to Join JGA
March 7, 2011
- Daiichi Sankyo to Acquire Plexxikon
March 7, 2011
- AZ Ordered to Pay Damages, Gov't Responsibility Denied: Iressa Trial
March 7, 2011
- Prazaxa Expected to Be Effective, Convenient: Prof. Uchiyama
March 7, 2011
- Develop Biomarkers with Therapeutic Agents: Dr Suzuki of Roche Pharma Japan
March 7, 2011
- Azilsartan Approved by FDA: Takeda
March 7, 2011
- BMKK Aims at Top-20 Position in Japan by 2015
March 7, 2011
- Novartis to Expand SOV for Equa through Comarketing with Sanofi-aventis
March 7, 2011
- JPO's Decision on Actos Patent Infringement Case Expected Soon
March 7, 2011
- FUJIFILM to Acquire 2 Contract Biopharmaceuticals Manufacturers from US Merck
March 7, 2011
- Aricept's Patent Period Extension Upheld by IP High Court
March 7, 2011
- Top 4 Products Neck and Neck in Global Market for Antibody Drugs
March 7, 2011
- Prof. Yamanaka, Dr Kondo of PMDA Discuss Toxicity Assessment for iPS Cells-Derived Products
March 7, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…